Rocket Pharmaceuticals RCKT
NASDAQ RCKT
$2.48 +0.03 (+1.22%)
At close: Nov 11, 2026 · 4:00 PM EST

Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures (2018)

Updated

Rocket Pharmaceuticals (RCKT) recorded Gains from Sales and Divestitures of -$5,000 in Q4 2018.

Analysis

Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures (2018) Analysis & Trends

For FY2018, Rocket Pharmaceuticals reported Gains from Sales and Divestitures of -$317,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Rocket Pharmaceuticals 268.37 Mn -15.33 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -5,000.00
Sep 30, 2018 -107,000.00
API Access

Rocket Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=RCKT&period=max&api_key=YOUR_API_KEY